Sessions

Distinct serotonergic systems regulate anxiety, depression, and impulsivity

[Speaker] Yu Ohmura:1
[Co-author] Kenji F Tanaka:2, Akihiro Yamanaka:3, Mitsuhiro Yoshioka:1
1:Department of Neuropharmacology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan, 2:Department of Neuropsychiatry, School of Medicine, Keio University, Japan, 3:Department of Neuroscience II, Research Institute of Environmental Medicine (RIEM), Nagoya University, Japan

Orexin/hypocretin receptor agonists: Pharmacological characterization of Nag 26 and discovery of novel agonist/potentiator structures based on the azulene scaffold

[Speaker] Jyrki P Kukkonen:1,2
[Co-author] Maiju K Rinne:1,3, Teppo O Leino:3, Ainoleena Turku:1,3, Pauli M Turunen:2, Yana Steynen:3, Henri Xhaard:3, Erik A Wallen:3
1:Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Finland, 2:Department of Physiology, Faculty of Medicine, University of Helsinki, Finland, 3:Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Finland

Safety and pharmacokinetics of single and repeated dose of a novel formulation of intra-nasal Oxytocin (TTA-121) in healthy Japanese volunteers (double blind, placebo-controlled Phase 1 trial)

[Speaker] Chie Sakanaka:1,2
[Co-author] Ryoko Ihara:3, Akiko Kishi:2, Kenji Kirihara:4, Gaku Oguri:2, Mihoko Shibuya:2, Kazushi Suzuki:3, Keiko Ueda:2, Yumi Umeda-Kameyama:5, Mitsutaka Yakabe:5, Tomohiro Haga:2, Hidenori Yamasue:6
1:Phase 1 Unit, Clinical Research Support Center, The University of Tokyo Hospital, Japan, 2:Clinical Research Support Center, The University of Tokyo Hospital, Japan, 3:The Unit for early and exploratory clinical development, Clinical Research Support Center, The University of Tokyo Hospital, Japan, 4:Department of Neuropsychiatry, The University of Tokyo Hospital, Japan, 5:Department of Geriatric medicine, The University of Tokyo Hospital, Japan, 6:Department of Psychiatry, Hamamatsu University School of Medicine, Japan

GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS

[Speaker] Nigel H. Greig:1
[Co-author] David Tweedie:1, Yazhou Li:1, Daniela Lecca:1, Barry J Hoffer:2, Yun Wang:3, Miaad Bader:4, Chaim G Pick:4, Dong-Seok Kim:1,5
1:Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, USA, 2:Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, OH, USA, 3:Center for Neuropsychiatric Research, National Health Research Institutes, Zhunan, Miaoli County, Taiwan, 4:Department of Anatomy and Anthropology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel, 5:Peptron Inc., Yuseong-gu, Daejeon, Korea

Amelioration of antidepressant behavior by Granulocyte colony stimulating factor (GCSF) in depressed rats: Exploring the preclinical role of brain derived neurotrophic factor (BDNF) and neurotransmitters

[Speaker] Ajay Prakash:1
[Co-author] Kanwaljeet Chopra:2, Bikash Medhi:1
1:Pharmacology, Post Graduate Institute of Medical Education and Research, India, 2:Neuropharmacology division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Advanced Search